Axsome Therapeutics, Inc. · AXSM · Next earnings

Axsome Therapeutics, Inc. reports Monday, Feb 22, 2027

AXSM reports before market open with consensus EPS at $-0.07 and revenue at $282.4M. Last quarter: Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests

Reports Before market open109 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $-0.07 Calendar consensus
Consensus revenue $282.4M Calendar consensus
Report date Feb 22, 2027 Monday, date estimated
Session Before market open 109 days away

Where AXSM left off: FY2026 Q3

Full report

Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests

EPS surprise +60.6% Reported $-0.25 vs $-0.63
Revenue surprise +4.2% Reported $259.7M vs $249.2M
Stock move -5.8% Event window
Subsequent drift 0.0% Up to 20 sessions

The supplied analysis does not provide formal financial guidance. It describes planned clinical and label-expansion work, including an AXS-20 pivotal Phase III trial and an AXS-17 Phase III trial planned for H1 2027, and an AXS-05 smoking-cessation topline readout planned for H2 2027.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • AUVELITY growth depends on sustained adoption, including conversion from sampling to paid use.
  • Gross-to-net discounts and payer reimbursement could affect profitability and patient access.
  • Upcoming pipeline programs carry clinical and regulatory uncertainty.
  • Competitive pressure remains in major-depression and migraine markets.

Questions analysts left open

  • Sample-to-paid conversion for AUVELITY.
  • The trajectory of gross-to-net discounts and its effect on profitability.
  • Real-world adherence and copay affordability, particularly in Medicare Advantage.
  • Competitive dynamics, including against established products such as Rexulti.

Ask FN2 about AXSM next report

Choose a question to continue your research
What should I watch for in AXSM's next earnings report?How did AXSM guide last quarter, and is consensus above or below that?Give me the bull and bear case going into AXSM earnings.

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Get the AXSM recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent AXSM quarters

All AXSM earnings
-5.8%FY2026 Q3+3.8%FY2026 Q2+8.3%FY2026 Q1+0.6%FY2025 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.